Insmed (NASDAQ:INSM – Get Rating) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.11, MarketWatch Earnings reports. Insmed had a negative net margin of 217.35% and a negative return on equity of 87.87%. The company had revenue of $53.10 million during the quarter, compared to the consensus estimate of $53.36 million. During the same quarter in the prior year, the firm posted ($0.89) EPS. The firm’s quarterly revenue was up 32.1% on a year-over-year basis.
Shares of INSM traded down $2.41 during trading hours on Friday, reaching $20.59. 1,824,425 shares of the stock traded hands, compared to its average volume of 941,544. The company has a current ratio of 6.19, a quick ratio of 5.70 and a debt-to-equity ratio of 1.41. The stock has a fifty day simple moving average of $23.43 and a 200 day simple moving average of $25.42. Insmed has a 52 week low of $20.02 and a 52 week high of $34.44. The company has a market cap of $2.45 billion, a price-to-earnings ratio of -5.45 and a beta of 2.06.
In related news, CEO William Lewis sold 96,614 shares of the firm’s stock in a transaction dated Wednesday, March 23rd. The shares were sold at an average price of $23.16, for a total transaction of $2,237,580.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.63% of the stock is owned by company insiders.
INSM has been the subject of several research reports. SVB Leerink dropped their price objective on shares of Insmed from $57.00 to $52.00 and set an “outperform” rating for the company in a research note on Tuesday, February 22nd. Zacks Investment Research upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research report on Tuesday, May 3rd. StockNews.com initiated coverage on shares of Insmed in a research report on Thursday, March 31st. They set a “hold” rating for the company. Finally, The Goldman Sachs Group initiated coverage on shares of Insmed in a report on Wednesday, April 27th. They issued a “buy” rating and a $56.00 price target for the company. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $50.29.
Insmed Company Profile (Get Rating)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
- Get a free copy of the StockNews.com research report on Insmed (INSM)
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.